Clinical Efficacy of Ribavirin in the Treatment of Genital Herpes simplex Virus Infection
- 1 January 1981
- journal article
- research article
- Published by S. Karger AG in Chemotherapy
- Vol. 27 (2) , 139-145
- https://doi.org/10.1159/000237969
Abstract
48 patients participated in a double-blind placebo-controlled study conducted to evaluate the efficacy of ribavirin in the treatment of herpes simplex virus genital infection. Study design did not allow a conclusion regarding usefulness of the drug in preventing recurrences. Ribavirin treatment (800mg/day p.o.) for 10 days reduced disease severity and promoted recovery as compared with placebo treatment.Keywords
This publication has 5 references indexed in Scilit:
- The broad spectrum antiviral agent ribavirin inhibits capping of mRNABiochemical and Biophysical Research Communications, 1979
- Metabolism of 5-amino-1-β-d-ribofuranosyl- imidazole-4-carboxamide and related five-membered heterocycles to 5′-triphosphates in human blood and L5178Y cellsBiochemical Pharmacology, 1978
- A Multicentered Study of Lysine Therapy in Herpes simplex InfectionDermatology, 1978
- Inhibition of Vaccinia Virus Growth by the Nucleoside Analogue 1-beta-D-Ribofuranosyl-1,2,4-Triazole-3-Carboxamide (Virazole, Ribavirin)Journal of General Virology, 1976
- Clinical Cure of Herpes Simplex Keratitis by 5-Iodo-2'-DeoxyuridineExperimental Biology and Medicine, 1962